Connor, Clark & Lunn Investment Management (CC&L)’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.2M | Buy |
36,269
+29,477
| +434% | +$14.2M | 0.03% | 383 |
|
|
2026
Q1 | $3.34M | Buy |
+6,792
| New | +$3.69M | 0.01% | 807 |
|
|
2025
Q4 | – | Sell |
-4,917
| Closed | -$2.38M | – | 1779 |
|
|
2025
Q3 | $2.38M | Sell |
4,917
-57,904
| -92% | -$27M | 0.01% | 803 |
|
|
2025
Q2 | $25.5M | Buy |
62,821
+55,174
| +722% | +$23.1M | 0.09% | 200 |
|
|
2025
Q1 | $3.81M | Sell |
7,647
-30,392
| -80% | -$16.5M | 0.02% | 572 |
|
|
2024
Q4 | $19.8M | Sell |
38,039
-237
| -0.6% | -$130K | 0.09% | 172 |
|
|
2024
Q3 | $23.7M | Sell |
38,276
-72,810
| -66% | -$43.1M | 0.11% | 141 |
|
|
2024
Q2 | $61.4M | Buy |
111,086
+84,112
| +312% | +$48.2M | 0.26% | 87 |
|
|
2024
Q1 | $15.7M | Buy |
26,974
+26,465
| +5,199% | +$14.9M | 0.07% | 231 |
|
|
2023
Q4 | $270K | Sell |
509
-4,783
| -90% | -$2.32M | ﹤0.01% | 1197 |
|
|
2023
Q3 | $2.68M | Buy |
+5,292
| New | +$2.82M | 0.01% | 535 |
|
|
2023
Q2 | – | Sell |
-861
| Closed | -$496K | – | 1496 |
|
|
2023
Q1 | $496K | Sell |
861
-49,508
| -98% | -$27.9M | ﹤0.01% | 883 |
|
|
2022
Q4 | $27.7M | Buy |
50,369
+4,550
| +10% | +$2.41M | 0.16% | 105 |
|
|
2022
Q3 | $23.2M | Sell |
45,819
-1,515
| -3% | -$848K | 0.15% | 107 |
|
|
2022
Q2 | $25.7M | Sell |
47,334
-4,472
| -9% | -$2.46M | 0.16% | 110 |
|
|
2022
Q1 | $30.6M | Buy |
51,806
+9,437
| +22% | +$5.42M | 0.15% | 112 |
|
|
2021
Q4 | $28.3M | Sell |
42,369
-17,114
| -29% | -$10.7M | 0.14% | 133 |
|
|
2021
Q3 | $34M | Buy |
59,483
+13,774
| +30% | +$7.56M | 0.18% | 107 |
|
|
2021
Q2 | $23.1M | Sell |
45,709
-1,376
| -3% | -$649K | 0.12% | 156 |
|
|
2021
Q1 | $21.5M | Buy |
47,085
+44,566
| +1,769% | +$21.3M | 0.12% | 140 |
|
|
2020
Q4 | $1.17M | Sell |
2,519
-34,355
| -93% | -$16.1M | 0.01% | 606 |
|
|
2020
Q3 | $16.3M | Buy |
36,874
+2,989
| +9% | +$1.23M | 0.11% | 152 |
|
|
2020
Q2 | $12.3M | Buy |
33,885
+13,860
| +69% | +$4.65M | 0.09% | 181 |
|
|
2020
Q1 | $5.68M | Buy |
20,025
+13,575
| +210% | +$4.28M | 0.05% | 229 |
|
|
2019
Q4 | $2.1M | Buy |
+6,450
| New | +$1.96M | 0.01% | 409 |
|
|
2018
Q2 | – | Sell |
-9,975
| Closed | -$2.06M | – | 1101 |
|
|
2018
Q1 | $2.06M | Sell |
9,975
-19,225
| -66% | -$4.04M | 0.01% | 384 |
|
|
2017
Q4 | $5.54M | Sell |
29,200
-27,225
| -48% | -$5.22M | 0.03% | 277 |
|
|
2017
Q3 | $10.7M | Buy |
56,425
+45,575
| +420% | +$8.25M | 0.06% | 201 |
|
|
2017
Q2 | $1.89M | Buy |
+10,850
| New | +$1.82M | 0.01% | 397 |
|
|
2016
Q4 | – | Sell |
-14,500
| Closed | -$2.31M | – | 985 |
|
|
2016
Q3 | $2.31M | Buy |
14,500
+8,400
| +138% | +$1.29M | 0.02% | 344 |
|
|
2016
Q2 | $901K | Buy |
6,100
+2,800
| +85% | +$413K | 0.01% | 485 |
|
|
2016
Q1 | $467K | Sell |
3,300
-1,400
| -30% | -$188K | ﹤0.01% | 586 |
|
|
2015
Q4 | $667K | Buy |
+4,700
| New | +$627K | 0.01% | 504 |
|
|
2015
Q2 | – | Sell |
-3,150
| Closed | -$423K | – | 661 |
|
|
2015
Q1 | $423K | Sell |
3,150
-16,200
| -84% | -$2.09M | ﹤0.01% | 415 |
|
|
2014
Q4 | $2.42M | Sell |
19,350
-2,600
| -12% | -$316K | 0.02% | 209 |
|
|
2014
Q3 | $2.67M | Buy |
21,950
+200
| +0.9% | +$24.3K | 0.02% | 190 |
|
|
2014
Q2 | $2.73M | Buy |
21,750
+3,944
| +22% | +$464K | 0.02% | 212 |
|
|
2014
Q1 | $2.36M | Sell |
17,806
-20,900
| -54% | -$2.48M | 0.02% | 253 |
|
|
2013
Q4 | $4.58M | Buy |
38,706
+3,156
| +9% | +$314K | 0.04% | 163 |
|
|
2013
Q3 | $3.37M | Sell |
35,550
-5,800
| -14% | -$525K | 0.03% | 146 |
|
|
2013
Q2 | $3.69M | Buy |
+41,350
| New | +$3.44M | 0.04% | 132 |
|
Other funds holding TMO
Connor, Clark & Lunn Investment Management (CC&L)'s TMO Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) increased its Thermo Fisher Scientific (TMO) stake by 434% in Q2 2026, buying an estimated $14.2M and bringing the position to 36,269 shares worth $18.2M. The position accounts for 0.03% of the portfolio, ranked #383.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TMO in Q2 2013 and has held it in 41 quarters since. The position peaked at $61.4M in Q2 2024. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) held 36,269 shares of Thermo Fisher Scientific worth $18.2M as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) bought 29,477 Thermo Fisher Scientific shares in Q2 2026, an estimated $14.2M.
- Thermo Fisher Scientific made up 0.03% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #383 holding.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 41 quarters since.
- Connor, Clark & Lunn Investment Management (CC&L)'s Thermo Fisher Scientific position peaked at $61.4M in Q2 2024.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.